STOCK TITAN

Nuvectis Pharma Inc - NVCT STOCK NEWS

Welcome to our dedicated news page for Nuvectis Pharma (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvectis Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvectis Pharma's position in the market.

Rhea-AI Summary
Nuvectis Pharma announces upcoming scientific presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary
Nuvectis Pharma to present at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary
Nuvectis Pharma announces upcoming scientific presentations for NXP800 and NXP900 at cancer research conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
Rhea-AI Summary
Nuvectis Pharma initiates Phase 1a trial for NXP900, a novel SFK inhibitor for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
-
Rhea-AI Summary
Nuvectis Pharma to host virtual KOL event on September 14, 2023 to discuss clinical-stage drug candidates NXP800 and NXP900.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
-
Rhea-AI Summary
Nuvectis Pharma (NASDAQ: NVCT) announces CEO's participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
conferences
Rhea-AI Summary
Nuvectis Pharma, Inc. has announced that its drug NXP800 has been granted Orphan Drug Designation by the FDA for the treatment of cholangiocarcinoma. NXP800 is an oral small molecule with a novel mechanism of action that has shown promising results in preclinical cancer models. The drug is currently being evaluated in a Phase 1b clinical trial for platinum resistant, ARID1a-mutated ovarian carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
Nuvectis Pharma Inc

Nasdaq:NVCT

NVCT Rankings

NVCT Stock Data

124.74M
5.11M
57.21%
17.02%
4.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Fort Lee